Respiratory Tract Infections News and Research

RSS

Tarenflurbil drug does not appear to benefit Alzheimer’s patients

Although there were promising results in a phase 2 trial, patients with mild Alzheimer disease who received the drug tarenflurbil as part of a phase 3 trial did not have better outcomes on measures of cognitive decline or loss of activities of daily living compared to patients who received placebo, according to a study in the December 16 issue of JAMA.

15 Dec 2009

The National Fragile X Foundation awards $100,000 grant for study of minocycline in FXS children

The National Fragile X Foundation has awarded a translational research seed grant of $100,000 to Dr. Randi J. Hagerman at the UC Davis M.I.N.D. Institute in California for a study of minocycline in the treatment of children with fragile X syndrome (FXS). Hagerman is an internationally recognized clinician and clinical researcher on FXS, the most common cause of inherited mental impairment.

8 Dec 2009

Study shows herbal medicine is effective for treating acute rhinosinusitis

Rhinosinusitis is an inflammatory process involving one or more of the paranasal sinuses that typically follows a viral upper respiratory tract infection (RTI). The term ‘acute rhinosinusitis’ is used instead of ‘acute sinusitis’ because it is the currently internationally accepted terminology.

4 Dec 2009

Chinese SFDA approves Tianyin Pharmaceutical's Pediatric Fever and Cough Oral Liquid

Tianyin Pharmaceutical Co., Inc.,, a manufacturer and supplier of modernized traditional Chinese medicine ("TCM") based in Chengdu, China, today announced that it has received approvals from the Chinese State Food and Drug Administration (SFDA) to produce Pediatric Fever and Cough Oral Liquid in dosage form of 10 ml/tube (SFDA approval number Z20093060) and Antibacterial and Anti-inflammatory Capsules in dosage form of 0.27 gram/capsule (SFDA approval number Z20090855).

1 Dec 2009

FDA provides marketing clearance for Prodesse's ProParaflu+ assay

Gen-Probe Incorporated announced today that the US Food and Drug Administration (FDA) has cleared for marketing Prodesse's ProParaflu+(TM) assay, a molecular test that detects and differentiates parainfluenza 1, 2 and 3 viruses, which cause lower respiratory tract infections.

25 Nov 2009

Wide gap between perceived and real determinants of antibiotic prescription exists, says researcher

Antibiotic over-prescription is promoted by pediatricians' perception of parents' expectations. Research published in the open access journal BMC Pediatrics shows that pediatricians are more likely to inappropriately prescribe antibiotics for respiratory tract infections if they perceived parents were expecting a prescription.

6 Nov 2009

Breastfeeding: ADA position paper details health benefits for both infants and mothers

The American Dietetic Association has released an updated position paper on breastfeeding that details health benefits for both infants and mothers and encourages promotion of breastfeeding whenever possible.

4 Nov 2009

H1N1 vaccine: Discussions and debates

You can't avoid H1N1 media coverage. It's front-page news on the web, the presses, the airways. Vaccine details, or lack of, are spurring discussion and debate. And a lot of people are in a quandary about whether or not to have the H1N1 shot based on their personal views and the information disseminated for public knowledge.

4 Nov 2009

Medela to host Virtual Human Milk Collection Campaign

Medela today announced it will host a Virtual Human Milk (breastmilk) Collection Campaign in honor of the March of Dimes' National Prematurity Awareness Month and the thousands of dedicated Neonatal healthcare professionals nationwide.

2 Nov 2009

Arzerra drug approved by FDA for treating chronic lymphocytic leukemia

The U.S. Food and Drug Administration today approved Arzerra (ofatumumab) for patients with chronic lymphocytic leukemia (CLL), a slowly progressing cancer of the blood and bone marrow.

27 Oct 2009

Fero Industries to acquire Pyro Pharmaceuticals

Fero Industries, Inc. (the “Company”) is pleased to announce that the Company has entered into a Definitive Agreement to acquire Pyro Pharmaceuticals, Inc. of Irvine, California.

15 Oct 2009

Bad breath can be treated

All of us have experienced bad breath at some point. However, suffering from chronic bad breath, or halitosis, can be embarrassing and affect your self-esteem and relationships with family, friends and coworkers. The good news -- bad breath is often preventable and easily treated.

12 Oct 2009

Studies show vitamin D plays an important role in preventing respiratory infections

Several studies and articles published this year show that vitamin D plays an important role in the prevention of respiratory infections such as the cold and flu.

1 Oct 2009

Cimzia approved for treating adult patients with rheumatoid arthritis

UCB Canada Inc. announced today that Health Canada has approved Cimzia, the only PEGylated anti-TNF (Tumor Necrosis Factor), for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA).

1 Sep 2009

MedImmune funds study on RSV disease among premature infants

MedImmune continues to advance its commitment to pediatric research with today's announcement of the first observational prospective study designed to assess the burden of respiratory syncytial virus (RSV) among preterm infants 32-to-35 weeks gestational age (GA) in outpatient settings during their first year of life.

30 Jun 2009

Pneumococcal vaccine effective in preventing severe pneumonia

A new trial has found that pneumococcal vaccine is effective in preventing severe pneumonia, the leading cause of death among children in developing countries. Co-ordinated by the National Institute for Health and Welfare (THL) between 2000 and 2004, a large scale efficacy trial - first of its kind in Asia - was carried out in the Philippines to investigate the effect of an investigational pneumococcal vaccine.

16 Jun 2009